A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila® with the Pharmaceutical Active Ingredient Recombinant L-Asparaginase in Adult Subjects with Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia
Latest Information Update: 03 Apr 2026
At a glance
- Drugs Asparaginase (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Medac
Most Recent Events
- 30 Mar 2026 Actual primary completion date changed from 29 Apr 2025 to 16 Nov 2025.
- 30 Mar 2026 Status changed from active, no longer recruiting to discontinued.
- 22 Aug 2025 Status changed from recruiting to active, no longer recruiting.